Fibrosis
Drug research and approvals for fibrosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 754 studies of fibrosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 141 drug trials for it since 2013, FDA has 33 approved and 179 open orphan designations naming it, and the EU has 21 authorised medicines for it.
- Recruiting worldwide: 754
- Trials authorized in Canada: 141
- FDA orphan approvals: 33
- EU medicines: 21
Recruiting Now
Newest start dates first, of 754 recruiting on ClinicalTrials.gov ↗- Post-Operative Use of FS2 to Mitigate Scarring in Burn PatientsNCT06807021 · Phase 2 / Phase 3 · Birch BioMed Inc · starts Mar 1, 2027
- Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine,…NCT07083557 · Not reported · Bettina Mittendorfer · starts Jan 1, 2027
- A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With…NCT07805785 · Phase 3 · Insmed Incorporated · starts Dec 1, 2026
- Pre-marketing Trial to Assess Safety and Efficacy of 'Volumizing Filler Based on Hyaluronic Acid and Recombinant…NCT06336044 · Not applicable · Taumedika s.r.l. · starts Nov 1, 2026
- The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated CirrhosisNCT07920744 · Not reported · Fifth Affiliated Hospital, Sun Yat-Sen University · starts Oct 28, 2026
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT07854782 · Phase 3 · Regeneron Pharmaceuticals · starts Oct 28, 2026
- Disposable Noninvasive Skin Closure for Promoting Postoperative Wound Healing and Preventing Surgical Skin ScarringNCT07849010 · Not applicable · Peking University Third Hospital · starts Oct 8, 2026
- Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisNCT07848191 · Phase 4 · Madrigal Pharmaceuticals, Inc. · starts Oct 7, 2026
- Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLDNCT07877272 · Not reported · University Hospital Muenster · starts Oct 5, 2026
- Optimal Treatment Strategy for Spontaneous Bacterial PeritonitisNCT07923318 · Not applicable · Chonnam National University Hospital · starts Oct 4, 2026
Drug Pipeline
5 approved, 1 in phase 3, 5 in phase 2, 10 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Ribavirin, Phytonadione, Furosemide, Spironolactone, Ethacrynic acid
- Peginterferon ALFA-2B
- Phase 3 Interferon alpha/beta receptor agonist
- Pentoxifylline
- Phase 2 Adenosine A2 receptor antagonist
- Vitamin e
- Phase 2
- Pravastatin
- Phase 2 HMG-CoA reductase inhibitor
- Lenumlostat
- Phase 2 Lysyl oxidase homolog 2 inhibitor
- Nerandomilast
- Phase 2
- Dazcapistat
- Phase 1
- Diphenhydramine
- Phase 1 Histamine H1 receptor antagonist
- Famotidine
- Phase 1 Histamine H2 receptor antagonist
- Ursodiol
- Phase 1 Bile acid receptor FXR agonist
- Interferon
- Phase 1
- Bifendate
- Phase 1
- Pirfenidone
- Phase 1 Unknown
- Olitigaltin
- Phase 1 Galectin-3 inhibitor
- Ziritaxestat
- Phase 1 Autotaxin inhibitor
- Fapi GA-68
- Early phase 1
How Its Trials Ended
3,487 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 781 whose ending is known, 41% met their primary endpoint, 10% missed it and 49% stopped early.
- Completed, result not reported1,43641%
- Ongoing72521%
- Status unknown54516%
- Met its primary endpoint3229%
- Stopped: other or unclear2046%
- Stopped: enrollment or feasibility862%
- Missed its primary endpoint802%
- Stopped: lack of efficacy371%
- Stopped: sponsor or business decision321%
- Stopped: funding120%
- Stopped: safety80%
Trials Authorized in Canada
The 10 newest of 141; search them all in Canada trials| Nov 10, 2026 | A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose range finding study to evaluate the efficacy, safety, and…CSL787 | CSL | Pending |
| Oct 23, 2026 | A randomised, double-blind, placebo-controlled phase IIa trial to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety, and tolerability of bi…BI 3810477 | Boehringer Ingelheim (Canada) Ltd Ltee | Pending |
| Aug 21, 2026 | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of nalbuphine extended-release tablets for the treatment of chronic…Nalbuphine | Trevi Therapeutics Inc | Pending |
| Jul 3, 2026 | A phase 2, multicenter, randomized, active-controlled study to assess the safety and efficacy of ang003 at two different dose levels in subjects with exocrine…ANG003 (lipase V325, protease, amylase) / creon | Anagram Therapeutics, Inc. | Pending |
| Jun 26, 2026 | A randomized, double-blind, head-to-head phase 3 trial to evaluate the efficacy and safety of lyt-100 (deupirfenidone) compared to pirfenidone at 52 weeks in…Deupirfenidone (LYT-100) / pirfenidone | Puretech Lyt 100, Inc | Ongoing |
| May 29, 2026 | Nerandomilast added to mycophenolate for treatment of pulmonary fibrosis (neram-pf): a single-arm prospective studyNerandomilast (bi 1015550) | Ubc Centre For Heart Lung Innovation, St. Paul'S Hospital | Ongoing |
| Apr 17, 2026 | A randomized, double-blind, placebo-controlled, phase 2 clinical trial of the efficacy and safety of mnkd-201 (nintedanib dry powder inhalation) in patients…Nintedanib (MNKD-201) | MannKind | Ongoing |
| Apr 10, 2026 | A phase IIb study to evaluate the efficacy, safety, and tolerability of azd8965 in participants with idiopathic pulmonary fibrosis (ipf) (arginaut)AZD8965 | AstraZeneca Pharmaceuticals | Ongoing |
| Apr 7, 2026 | An open-label, multi-center, long-term extension study to evaluate the long-term safety and tolerability of admilparant in participants with pulmonary fibrosisAdmilparant (BMS-986278) | Bristol-Myers Squibb | Pending |
| Mar 20, 2026 | A randomized, double-blinded, placebo-controlled, parallel-group, phase 2a participants with non-cystic fibrosis bronchiectasis (ncfb) study to assess the…SAR445399 | Sanofi-Aventis Canada Inc | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 212| Mar 27, 2026 | AlyftrekTreatment of cystic fibrosis (CF) in adult and pediatric patients 6 years of age and older who have a clinical diagnosis of CF and who have… | Vertex Pharmaceuticals Incorporated | Approved |
| Mar 27, 2026 | TrikaftaTreatment of cystic fibrosis (CF) in adult and pediatric patients aged 2 years and older who have a clinical diagnosis of CF and who have… | Vertex Pharmaceuticals Incorporated | Approved |
| Oct 7, 2025 | JascaydTreatment of idiopathic pulmonary fibrosis (IPF) in adult patients | Boehringer Ingelheim Pharmaceuticals, Inc. | Approved |
| Dec 20, 2024 | AlyftrekTreatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del mutation or another responsive… | Vertex Pharmaceuticals Incorporated | Approved |
| Dec 20, 2024 | TrikaftaTreatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis… | Vertex Pharmaceuticals Incorporated | Approved |
| May 3, 2023 | KalydecoTreatment of cystic fibrosis (CF) in patients age 1 month and older who have at least one mutation in the CFTR gene that is responsive to… | Vertex Pharmaceuticals, Inc. | Approved |
| Apr 26, 2023 | TrikaftaTreatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis… | Vertex Pharmaceuticals Incorporated | Approved |
| Sep 2, 2022 | OrkambiTreatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene | Vertex Pharmaceuticals Inc. | Approved |
| Jun 8, 2021 | TrikaftaTreatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis… | Vertex Pharmaceuticals Incorporated | Approved |
| Dec 21, 2020 | TrikaftaTreatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis… | Vertex Pharmaceuticals Incorporated | Approved |
| Dec 21, 2020 | SymdekoTreatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one… | Vertex Pharmaceuticals Inc. | Approved |
| Dec 21, 2020 | KalydecoTreatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance… | Vertex Pharmaceuticals, Inc. | Approved |
| Oct 30, 2020 | Bronchitol®As add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use… | Pharmaxis Europe Limited | Approved |
| Sep 24, 2020 | KalydecoKALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene… | Vertex Pharmaceuticals, Inc. | Approved |
| Oct 21, 2019 | TrikaftaTRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation… | Vertex Pharmaceuticals Incorporated | Approved |
Medicines Authorised in the EU
Newest first; 15 of 21Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA